Chlamydia Articles & Analysis
12 news found
CCHCI among first healthcare providers in the nation to adopt new handheld PCR technology to detect gonorrhea, chlamydia and trichomoniasis in a single visit. Chiricahua Community Health Centers, Inc. ...
Visby Medical, Inc. an innovative diagnostic company, today announced its agreement with Urgent Care for Children (UC4C) to offer the company’s new Sexual Health Click Test to patients for the detection of sexually transmitted infections (STIs) in female patients 14 years of age and older. The device can detect chlamydia, gonorrhea, and trichomoniasis, three of the most ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first ...
Chief Executive Officer Saundra Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate) as well as the Company's pipeline, including the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and the recently announced ...
Top-line data is expected from Evofem's pivotal Phase 3 trial for the prevention of chlamydia and gonorrhea in women in the second half of 2022. 1 Veazey et al. ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first ...
Visby Medical™, a leading medical diagnostic company, today announced results from the cross-sectional single visit patient outcomes and implementation study, which evaluated self-collected vaginal swab samples from 55 women using the Visby Medical Sexual Health Click Test for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV). ...
Other products included in the agreement will focus on the expanding need to test for additional sexually transmitted infections beyond Chlamydia and Gonorrhea. The agreement will provide a broader based distribution of ELITechGroup MGB Alert Analyte Specific Reagents. ...
The latest educational video discusses psittacosis and Chlamydia psittaci. Psittacosis is an infectious disease usually transmitted to humans from birds in the parrot family as well as from turkeys and pigeons. ...